Jade Biosciences (JBIO) Cash from Operations (2020 - 2026)
Jade Biosciences' (JBIO) quarterly Cash from Operations came in at 24100000.0 in Q1 2026, down 28.49% YoY from 33699396.15 in Q1 2025, and up 28.4% on a QoQ basis from 33660000.0 in Q4 2025.
Powered by 
Analysis
Jade Biosciences (JBIO) Cash from Operations (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of Cash from Operations data on file, last reported at 24100000.0 in Q1 2026.
- Quarterly Cash from Operations fell 28.49% year-over-year to 24100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 100043000.0 (down 107.67% YoY) and the FY2025 annual result came in at 94700000.0, down 33.01% from the prior year.
- Cash from Operations grew to 24100000.0 in Q1 2026, from 33660000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 5661000.0 in Q1 2022 to a low of 33660000.0 in Q4 2025.
- A 5-year average of 16736812.5 and a median of 15277000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 56.43% — and 2025, when it slumped 225.26%.
- Tracing JBIO's Cash from Operations over 5 years: stood at 14865000.0 in 2022, then gained by 0.44% to 14800000.0 in 2023, then plunged by 52.8% to 22614000.0 in 2024, then sank by 48.85% to 33660000.0 in 2025, then climbed by 28.4% to 24100000.0 in 2026.
- The last three Cash from Operations figures came in at 24100000.0 (Q1 2026), 33660000.0 (Q4 2025), and 22124000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Jade Biosciences | 1.22 Bn | 1.22 Bn | - | -43.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43.64 Mn |
| Mar 31, 2026 | -24.10 Mn |
| Dec 31, 2025 | -33.66 Mn |
| Sep 30, 2025 | -22.12 Mn |
| Jun 30, 2025 | -20.16 Mn |
| Mar 31, 2025 | -18.76 Mn |
| Dec 31, 2024 | -22.61 Mn |
| Sep 30, 2024 | -6.80 Mn |
| Mar 31, 2024 | -23.67 Mn |
| Dec 31, 2023 | -14.80 Mn |
| Sep 30, 2023 | -15.61 Mn |
| Jun 30, 2023 | -14.94 Mn |
| Mar 31, 2023 | -11.42 Mn |
| Dec 31, 2022 | -14.87 Mn |
| Sep 30, 2022 | -9.72 Mn |
| Jun 30, 2022 | -8.88 Mn |
| Mar 31, 2022 | -5.66 Mn |
| Dec 31, 2021 | -13.09 Mn |
| Sep 30, 2021 | -6.53 Mn |
| Jun 30, 2021 | -4.01 Mn |